| ●Editorial | Iwamoto K | 220 | Full text | |
| ●The 19th International Conference in Pharmaceutical Medicine (ICPM) 2018 (Tokyo): The Future of Medicines Development |
||||
| Overview: Outcome of ICPM2018 in Tokyo and expectations from ICPM2020 in Rome | Imamura K | 221-5 | ||
| Greetings | Yokokura Y | 227-8 | ||
| Welcome message: ICPM 2018 | Silva H，Iwamoto K， Imamura K，Nishiuma S （Trans. by Nishiuma S） | 229-30 | ||
| Keynote Lecture 1: Changing role of biomedical professionals in medicines development | Kloiber O （Trans. by Kurihara C） | 231-42 | ||
| Keynote Lecture 2: Future of health-related biotechnology in Japan | Suzuki Y （Trans. by Kurihara C） | 243-57 | ||
| ・The 19th ICPM: Workshops and Panel Discussion | ||||
| Workshop 1: Innovations in clinical trials | Iwamoto K，Klingmann I （Trans. by Iwamoto K） | 259-60 | ||
| Workshop 2: Ethics in medicines development | Kurihara C，Kerpel-Fronius S （Trans. by Kurihara C） | 261-2 | ||
| Workshop 4: Patient-centered medicines development (Roundtable) | Klingmann I （Trans. by Imamura K） | 263-4 | ||
| Panel Discussion: Medical Affairs and MSLs | Silva H，Vandenbroucke P （Trans. by Matsuyama K） | 265-7 | ||
| Workshop 6: Good Publication Practice | Kurihara C，Dubois D （Trans. by Kurihara C） | 269-71 | ||
| Workshop 8: Best Practices in Pharmaceutical Medicine | Matsuyama K，Jurczynska A （Trans. by Matsuyama K） | 273-5 | ||
| ●Translations | ||||
| The shared ethical responsibility of medically and non-medically qualified experts in human drug development teams | Kerpel-Fronius S， Becker S，Barrett J，et al． （Trans. by Kurihara C） |
277-84 | Abstract | |
| IFAPP INTERNATIONAL ETHICS FRAMEWORK FOR PHARMACEUTICAL PHYSICIANS AND MEDICINES DEVELOPMENT SCIENTISTS (PPs & MDSs) | IFAPP （Trans. by Kurihara C） |
285-302 | Full text | |
| ●Article | ||||
| Patient-centric drug development and innovative data strategy | Imamura K | 303-14 | Abstract | |
| ●The 19th ICPM: Original English versions of the lectures and workshop summaries | ||||
| Keynote Lecture 1: Changing role of biomedical professionals in medicines development | Kloiber O | 315-26 | Full text | |
| Keynote Lecture 2: Future of health-related biotechnology in Japan | Suzuki Y | 327-41 | Full text | |
| Workshop 1: Innovations in clinical trials | Iwamoto K，Klingmann I | 343-4 | Full text | |
| Workshop 2: Ethics in medicines development | Kurihara C，Kerpel-Fronius S | 345-6 | Full text | |
| Workshop 4: Patient-centered medicines development (Roundtable) | Klingmann I | 347-8 | Full text | |
| Panel Discussion: Medical Affairs and MSLs | Silva H，Vandenbroucke P | 349-51 | Full text | |
| Workshop 6: Good Publication Practice | Kurihara C，Dubois D | 353-5 | Full text | |
| Workshop 8: Best Practices in Pharmaceutical Medicine | Matsuyama K，Jurczynska A | 357-9 | Full text | |
| ●Instructions for authors［Japanese］＆［English］ | 361-9 | Full text | ||
| ●Editor's note | Hirotsu C | 371 | Full text | |